Breast Cancer Coverage from Every Angle
Advertisement
Advertisement

Priya Rastogi, MD, on a Novel Approach to Predicting Benefit From Extended Letrozole Treatment for Breast Cancer

Posted: Wednesday, July 14, 2021

Priya Rastogi, MD, of the University of Pittsburgh, talks about how the 70-gene MammaPrint assay was used to identify subgroups of women with breast cancer for whom extended letrozole therapy is likely to be useful in extending disease-free survival, and the implications for clinical practice.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.